Gilead stock toppled Thursday after CVS HealthCVS said it won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now. The decision is based on clinical, financial and ...
CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results